TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer

Josephine Hai1,2,3,4, Chang-Qi Zhu1, Tao Wang1, Shawna L. Organ1, Frances A. Shepherd1 & Ming-Sound Tsao1,2

Non-small-cell lung carcinoma (NSCLC) accounts for 85% of malignant lung tumors and is the leading cause of cancer deaths. Our group previously identified Tripartite Motif 14 (TRIM14) as a component of a prognostic multigene expression signature for NSCLC. Little is known about the function of TRIM14 protein in normal or disease states. We investigated the functional and prognostic role of TRIM14 in NSCLC using in vitro and in vivo perturbation model systems. Firstly, a pooled RNAi screen identified TRIM14 to effect cell proliferation/survival in NSCLC cells. Secondly, silencing of TRIM14 expression significantly enhanced tumor growth in NSCLC xenograft mouse models, while exogenous TRIM14 expression attenuated tumorigenesis. In addition, differences in apoptotic activity between TRIM14-deficient and control tumors suggests that TRIM14 tumor suppressor activity may depend on cell death signaling pathways. TRIM14-deficient cell lines showed both resistance to hypoxia-induced cell death and attenuation of interferon response via STAT1 signaling. Consistent with these phenotypes, multivariate analyses on published mRNA expression datasets of over 600 primary NSCLCs demonstrated that low TRIM14 mRNA levels are significantly associated with poorer prognosis in early stage NSCLC patients. Our functional data therefore establish a novel tumor suppressive role for TRIM14 in NSCLC progression.
Here, we have combined a genetic screen, clinical data, functional assays and in vivo xenograft models to provide strong evidence that TRIM14 plays a novel tumor-suppressive role in lung cancer.

**Materials and Methods**

**In silico prognostic evaluation of TRIM14 expression.** To assess the prognostic value of TRIM14 expression, in silico analyses were performed on published microarray data from four patient cohorts. JBR.10 was a phase 3 randomized trial of adjuvant chemotherapy (cisplatin and vinorelbine) versus observation in stage IB-II patients. The prognostic value of TRIM14 was assessed in the expression data of 62 patients in the observation arm. The National Cancer Institute Directors’ Challenge Consortium (DCC) cohort included 442 adenocarcinoma patients from 4 North American cancer centers. Excluding patients from the JBR.10 cohort contributed into this DCC study and patients who received adjuvant chemo/radiotherapy, expression data from the 311 patients were used for prognostic analysis. The University of Michigan cohort consisted of 129 stage I-III squamous cell carcinomas. The University Health Network cohort consisted of 181 stage I-II NSCLCs. Gene expression analyses from the above 3 cohorts were performed using the Affymetrix U133A microarray. The association of the expression of TRIM14 and survival was evaluated using Cox proportional hazards regression in SAS v9.2 (SAS Institute) with gene expression as a continuous variable. Datasets in this publication are accessible through the National Center for Biotechnology Information Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) through GEO Series accession number GSE68465, GSE4573 and GSE14814, respectively.

**Cell culture.** Human NSCLC cell lines NCI-H1650, H520, H157, H358, H3255 and H3195 were obtained from the American Type Culture Collection (ATCC; Manassas, VA) and cultured in RPMI-1650 media supplemented with 10% Fetal Bovine Serum (FBS; Hyclone Europe, Ltd., Cramlington, UK) and antibiotics. Human embryonic kidney 293T (HEK293T) cells were cultured in DMEM media supplemented with 10% FBS and antibiotics. All cells were cultivated at 37 °C and 5% CO₂. Authentication of human cell lines was done by short tandem repeat (STR) DNA profiling analysis (Supplemental Table 6). For anoxic treatment, cells were cultured in HypOxygen H85 workstation (Don Whitley Scientific) and the chamber atmosphere consisted of 5% H₂, 5% CO₂, <0.02% O₂ and 90% N₂.

**Lentiviral shRNA screen and stable isogenic cell line generation.** Each gene was targeted by four or five constructs obtained from the RNAi Consortium (TRC; Toronto, ON). Lentiviral shRNA expression vectors (pLKO.1 backbone) were transfected into 293T cells in culture plates using protocols from TRC (http://portals.broadinstitute.org/gpp/public/). Targets cells were infected with lentivirus at 0.4 multiplicity of infection according to TRC protocols. The medium containing 2 μg/ml puromycin was added 24 hours post transfection to select for cells stably transduced with short hairpin RNA (shRNA).

shRNA against human TRIM14 used for further experiments included: shTRIM14.A (TRCN0000061828), shTRIM14.B (TRCN0000061832), and non-specific control shGFP (TRCN0000072179). Human full length TRIM14 cDNA plasmid, pOTB7-TRIM14, was obtained commercially (4299815; Fisher Scientific, Waltham, MA) and was subcloned into our modified Gateway recombination lentiviral expression vector, pLKO.puro. DEST18, containing a puromycin selection marker. All vectors were sequence confirmed.

Transfected cells were used for further experiments including: shTRIM14.A (TRCN0000061828), shTRIM14.B (TRCN0000061832), and non-specific control shGFP (TRCN0000072179). Human full length TRIM14 cDNA plasmid, pOTB7-TRIM14, was obtained commercially (4299815; Fisher Scientific, Waltham, MA) and was subcloned into our modified Gateway recombination lentiviral expression vector, pLKO.puro. DEST18, containing a puromycin selection marker. All vectors were sequence confirmed.

Western blot analysis, antibodies and immunohistochemistry. Whole cell extracts were lysed with lysis buffer (10 mM Tris [pH 8.0], 1% NP-40, 2 mM EDTA, 150 mM, 0.1 mM Na₂VO₄ and protease inhibitors [Roche]), resolved by SDS-PAGE and transferred to polyvinylidene fluoride membranes. Primary antibodies included: anti-TRIM14 (Proteintech), FLAG M2 affinity gel, Protein G-agarose beads, β-actin (Sigma), AIF (Invitrogen), p62, HAX1 (Genetex), phosphor-STAT1 (Cell Signaling), STAT1 (Invitrogen). After blocking, membranes were incubated with relevant antibodies and probed with corresponding HRP-conjugated secondary antibodies (Cell Signaling). All films were developed with ECL-Plus reagents (GE healthcare, Piscataway, NJ). Formalin-fixed paraffin-embedded tissues were cut at 4-μm thickness and dried in a 60 °C oven overnight. Immunohistochemistry was performed using the peroxidase anti-peroxidase technique following a microwave antigen retrieval procedure. Ki67 and cleaved caspase-3 antibodies were used at 1:500 dilution following pepsin digestion. Whole slides were scanned using the Aperio Scanscope XT (Vista, CA). Percentage of cells with positive Ki67 or cleaved caspase-3 staining were independently blind scored (TW and JH).

Immunoprecipitation for liquid chromatography-tandem mass spectrometry (LC-MS/MS). Forty-eight hours after transfection, cells were lysed and equal amounts of extract were precleared using Protein G-agarose beads (Sigma). Extracts were incubated separately with anti-FLAG affinity gel overnight at 4 °C. After washing the immunoprecipitates, bound protein complexes were eluted using 0.15% trifluoroacetic acid (TFA), reduced using 45 mM dithiothreitol and incubated with 1 μg TPCK trypsin overnight. Trypsinized peptides were acidified with 20% TFA, purified using C-18 spin columns (Pierce, IL, USA) and vacuum concentrated. The samples were loaded onto a 75 μm ID X 50 cm (2 μm C18) analytical column (EASY-Spray, Thermo-Fisher Scientific, Odense Denmark). The peptides were eluted over 2 hours at 250 nL/minute using a 0 to 35% acetonitrile gradient in 0.1% formic acid using an EASY nLC 1000 nano-chromatography pump (Thermo-Fisher Scientific, Odense Denmark). The peptides were eluted into a LTQ Velos-Orbitrap Elite hybrid mass spectrometer (Thermo-Fisher, Bremen, Germany) operated in a data dependant mode. MS was acquired at 240,000 FWHM resolution in the FTMS (using a target value of 5 × 10⁵ ions) and MS/MS was carried out in the linear ion trap. 10 MS/MS scans were calculated for each precursor ion.
were obtained per MS cycle using a target of $1 \times 10^4$ ions and a maximum injection time of 50 ms, and all ions passing the monoisotopic precursor selection (MIPS) filter were fragmented.

**MTS cell proliferation, colony formation and apoptosis assays.** Cell proliferation/viability was evaluated by the tetrazolium dye (MTS) assay (Promega, Madison, WI). Each cell line was plated at a seeding density to give logarithmic growth over the course of the assay in a 96-well tissue culture plate. The concentration of final product is measured by absorbance at 490 nm and is proportional to the viable cell number in each well. For soft agar assays, $5 \times 10^3$ to $10^6$ cells were suspended in 0.8% low melting point agarose (Difco Laboratories Inc., Detroit, MI) at room temperature, mixed with an equal volume of 2x concentrated culture media, and plated onto an agarose bed consisting of 2% low melting point agarose and the same medium. After 3–6 weeks, colonies were stained with neutral red and were enumerated using a Leica MZ FLIII Stereomicroscope (Leica, Germany).

Apoptosis was determined using the Annexin V assay (Biolegend, San Diego, CA) and cell cycle was analyzed using the Propidium Iodide assay (Invitrogen, MA). After treatment, cells were collected and stained with Annexin V-FITC and/or propidium iodide solution as per the manufacturer’s protocol and analyzed by flow cytometry. Cell death was recorded in a FACSCanto II (BD Biosciences, Mississauga, ON) in the total population (10,000 cells) and data were analyzed using FACSCanto II software and ModFit Software (Verity Software House, Topsham, ME).

**Animals and subcutaneous tumorigenicity assays.** Severe combined immunodeficient (SCID) and Non-obese diabetic severe combined immunodeficient (NOD-SCID) mice were bred on site and obtained from the Ontario Cancer Institute (OCI; Toronto, ON) animal facility. All manipulations were performed under sterile conditions in a laminar flow hood, in accordance with procedures approved by the OCI Animal Care Committee. H1650 (3 $\times$ 10$^6$) and H157 (2 $\times$ 10$^6$) cells were injected subcutaneously in the right flank of 6-week-old SCID mice ($n = 7$–10 per group). Two million cells of H3255 cells were injected into 6-week-old NOD-SCID mice. Mice were examined every 2–3 days, and tumor length and width were measured using calipers. Tumor volume was calculated using the following formula: $(\text{length} \times \text{width}^2)/6$. Mice were sacrificed once the humane endpoint (~1.5 cm diameter) was reached. At sacrifice, portions of tumors were snap-frozen and stored in liquid nitrogen or were fixed in 10% buffered formalin for routine histopathologic processing.

**In vivo ubiquitylation assays.** Forty-eight hours post transfection, HEK293T cells expressing HA-Ub and 3xFLAG-TRIM14 were treated with 10μM of MG132 for 4 hours. After treatment, the cells were washed twice and lysed with lysis buffer containing 2 mM N-ethylmaleimide, which blocks most deubiquitylating enzyme activity. Extracts were denatured by adding 1% SDS followed by boiling for 10 min. Lysates were then exchanged with lysis buffer containing 1% Triton X-100 and incubated on ice for 30 min. Cleared lysates were quantified and an equal amount of each lysate was used for immunoprecipitation with anti-FLAG M2 affinity gel. Beads were washed with lysis buffer three times and boiled in SDS-PAGE sample buffer with β-mercaptoethanol for 5 min before separation on a SDS-PAGE gel.

**Statistics.** All data are presented as mean ± SEM. Statistical significance was determined using two-tailed Student’s t test and mixed-model ANOVA for colony formation and MTS assay, respectively. Difference in tumor growth rates of xenografts was tested using mixed-model ANOVA. Tests that produced $P \leq 0.05$ were considered to be significant. All statistical analyses were performed with GraphPad Prism 6.0 (La Jolla, CA).

**Ethics approval.** All animal experiments were performed in accordance with procedures approved by the Ontario Cancer Institute (Toronto, ON) Animal Care Committee.

**Results**

TRIM14 negatively affects proliferation/survival of NSCLC cell lines in vitro. We previously identified a prognostic multigene expression signature for early-stage NSCLC patients and hypothesized that these genes may function in the development and/or progression of NSCLC$^{10}$. To identify proteins affecting the cell proliferation/survival of NSCLC cells, we performed a screen using a library of about 100 short-hairpin RNAs (shRNAs) against the genes in our signature. Briefly, H460 and H358 cells were transfected with individual shRNA oligos from the library, allowed to undergo multiple doubling periods to facilitate stable shRNA integration and expression, and harvested at multiple time points to assess the effect of each shRNA on cell proliferation over time (Fig. 1a). Reduction in the representation of 20 shRNAs corresponding to genes essential for cell viability (e.g., CDK11B, RPS14, etc.) showed that the screen was functional (Supplemental Figure 1). Interestingly, downregulation of TRIM14 expression enhanced cell proliferation/survival in both H358 and H460 as represented by hairpin enrichment over time (Fig. 1a).

To validate the functional role of TRIM14 as a putative tumor suppressor gene (TSG) in lung cancer, we first screened TRIM14 protein expression using Western blot analysis in twelve different NSCLC cell lines and an immortalized but non-tumorigenic human bronchial epithelial cell line (HBE135). TRIM14 protein levels varied substantially among NSCLC cell lines with six out of twelve lines having lower expression levels compared to HBE135 cells (Fig. 1b).

We next established a panel of NSCLC isogenic cell lines that stably expressed the TRIM14 open reading frame (ORF) or shRNAs against TRIM14. H1650, H520, H157 and H358 cell lines, which endogenously express TRIM14, were transduced with two independent shRNAs (shTRIM14.A and shTRIM14.B) or a vector control (shGFP) and downregulation efficiency assessed by quantitative RT-PCR and Western blot analysis (Fig. 1c and Supplemental Figure 2). Both shTRIM14.A and shTRIM14.B mediated a clear decrease in TRIM14 protein levels relative to the vector control. We further overexpressed TRIM14 ORF constructs in H1395 and H3255 cell
Figure 1. TRIM14 negatively affects proliferation/survival of NSCLC cell lines in vitro. (a) Schematic diagram illustrates the experimental design of the pooled RNAi screen to identify genes affecting cell proliferation/survival in H460 and H358. Deep sequencing was used to quantify TRIM14 shRNA representation in H460 and H358 cell populations at multiple time points for two independent shRNAs. (b) Profiling TRIM14 protein expression in a panel of human NSCLC cell lines of different histological subtypes via Western blot analyses. (c) Whole-cell extracts from cell lines stably expressing either full-length TRIM14 or shRNAs against TRIM14 were subjected to Western blot analysis with anti-TRIM14 antibody and compared with isogenic shGFP or empty vector (EV) controls. β-actin served as a loading control. (d) TRIM14 downregulation and overexpression in cells (red) affects cell viability as measured by MTS assays. (f) Soft agar was used to assess the ability to form colonies in isogenic cell lines. Results shown represent three biological replicates. (Two-tailed student's t-test, ****p < 0.0001).
lines with nearly undetectable endogenous TRIM14 protein levels (Fig. 1c). Stable integration of shRNA or overexpression constructs did not alter the morphology of the cells, which remained epithelial in appearance. Using MTS assays, we confirmed a significant increase in cell proliferation of H1650, H520 and H157 upon TRIM14 downregulation, consistent with our initial observation in H460 and H358 cells in the shRNA screen (Fig. 1d; p < 0.0001). Conversely, overexpression of TRIM14 in H1395 and H3255 cells significantly augmented the growth rate of H1395 and H3255 cells (Fig. 1d; p < 0.0001 and p = 0.0025, respectively). Furthermore, the exogenous expression of TRIM14 significantly decreased soft agar colony formation of H1395 cells, while downregulation of TRIM14 increased the number of colonies formed by H1650 and H157 cells (Fig. 1e).

Loss of TRIM14 contributes to tumorigenicity of NSCLC cell lines in vivo. We injected isogenic cell lines into subcutaneous tissue of scid mice to assess tumor growth rates. Overexpression of TRIM14 significantly attenuated tumor growth in H3255 xenograft models (Fig. 2a; p = 0.0021). Tumors formed by H3255-TRIM14 cells exhibited significantly reduced tumor weights than tumors formed by the empty vector controls (EV) at necropsy (Fig. 2b; p = 0.0314). Conversely, tumors formed by TRIM14-deficient cells (H1650 and H157) exhibited increased tumor growth rates and greater tumor weights than control tumors (Fig. 2c–e).

Immunohistochemical (IHC) detection of cell proliferation marker Ki67 in H1650 xenograft tumor sections did not show a significant difference between control and experimental groups (Fig. 3b). However, staining using apoptotic marker cleaved caspase-3 demonstrated a significant albeit modest decrease in the number of cells with active caspase-3 in H1650-shTRIM14 xenograft tumors compared to controls (Fig. 3a,b; p = 0.0064). Moreover, Western blot analyses on tumor lysates confirmed sustained silencing of TRIM14 protein levels in H1650 during tumor progression, which coincided with reduced protein expression of apoptosis-inducing factor (AIF), another caspase-independent apoptotic pathway (Fig. 3c). Given that we observed apoptotic changes rather than expression of Ki67 or proliferating cell nuclear antigen (PCNA), we speculate that TRIM14 expression mediates apoptotic and cell death signaling. Together these results suggest that TRIM14 behaves as a TSG in NSCLC xenografts.

Association of TRIM14 expression with survival of NSCLC patients. We previously identified TRIM14 as a component of a prognostic multigene expression signature for early-stage NSCLC patients. By analyzing the individual prognostic significance of TRIM14 expression in publicly available gene expression datasets of primary NSCLCs, we found that high TRIM14 mRNA levels in tumors correlate with better survival outcome after surgery, consistent with its antitumor activity (Table 1). The four published microarray studies represented a total of 683 early-stage surgically resected NSCLC patients who had not received adjuvant chemotherapy or...
radiotherapy. Univariate survival analyses revealed that patients with high TRIM14 expression survived longer than patients with low expression in the BR.10 patient cohort (hazard ratio [HR] = 0.22, 95% CI = 0.09–0.56, p = 0.002) and the Director’s Challenge Consortium (DCC) cohort (HR = 0.61, 95% CI = 0.40–0.94, p = 0.026). TRIM14 expression did not correlate with survival in the University of Michigan study, which included only squamous carcinoma patients (HR = 1.17, 95% CI = 0.48–2.83, p = 0.733) (Table 1). Multivariate analysis revealed significant associations between TRIM14 expression and survival when adjusted for histological subtype, stage, age and sex in DCC and BR.10 cohorts. This data further supports the notion that TRIM14 down-regulation promotes NSCLC progression, which may lead to a poor clinical outcome.

Table 1. Clinical correlation of TRIM14 expression in NSCLC patients. Abbreviations: DCC, Director’s Challenge Consortium adenocarcinoma; NSCLC, non-small cell lung cancer; UHN, University Health Network; U133A, Affymetrix U133A chip; ADC, adenocarcinoma; SQC, squamous cell carcinoma. *Hazard ratio compares the overall survival of the high-risk (poor prognosis) patient group to that of the low-risk (good prognosis) group.

Figure 3. Reduced tumor growth of TRIM14-deficient cells correlates with decreased apoptotic activity in vivo. (a,b) Representative histologic sections of xenografts of H1650 tumors were immunostained with Ki67 and cleaved-caspase-3 (CC3) antibody and the number of positive cells were quantified for 10 fields at high power (n = 10 controls; n = 8 shTRIM14.B; scale bar = 300 μm). (c) Total extracts from H1650 and H3255 xenograft tumors were subjected to Western blot analysis using the indicated antibodies and compared to isogenic controls. β-actin and GAPDH was used as loading controls. (Abbreviations: EV = Empty vector; Two-tailed student’s t-test; ****p < 0.0001, ns: not significant).
TRIM14 sensitizes NSCLC cells to anoxic-induced cell death. Given the biological implications of the in vivo results, we sought to understand the mechanism of TRIM14’s antitumor activity. We first analyzed the effect of TRIM14 downregulation on cell cycle progression by employing flow cytometry after propidium iodide staining. No significant effect on the distribution of G1, S or G2/M-phase cell populations was observed (Fig. 4a). Next, to determine whether TRIM14 may be inhibiting cell death pathways we assessed the effect of various apoptotic stimuli on TRIM14-deficient cells. While Staurosporine and Cisplatin treatment had no differential apoptotic effects on TRIM14-deficient cells compared to controls, apoptosis was significantly attenuated under anoxic conditions (<0.02% PO2 hypoxia) in TRIM14-deficient cells (H1650 and H358), suggesting that these cells were resistant to hypoxia-induced cell death (Fig. 4c,d; p < 0.0001 and 0.0133, respectively; Supplemental Figure 3). Furthermore, downregulation of TRIM14 showed no effect on phosphorylation status of extracellular signal-regulated kinase (ERK) and serine/threonine kinase (AKT), two classic signaling molecules involved in cell proliferation and survival (Supplemental Figure 4). This result suggests that TRIM14 reduces growth of NSCLC cells primarily by affecting cell death pathways, rather than by inhibiting proliferative signaling.

Loss of TRIM14 attenuates interferon response in NSCLC cells. Because previous studies have implicated the TRIMs as critical regulators in innate immune responses, we hypothesized that TRIM14 may exert antitumor cell effects via interferon signaling pathways in lung cancer cells16,17. Downregulation of TRIM14 attenuated interferon-γ (IFN-γ)-induced activation of signal transducer and activator of transcription 1 (STAT1) phosphorylation at tyrosine 701 in cells over time. Western blot analysis of IFN-γ-treated H1650 control cells (10 units/ml [U]) revealed that phospho-STAT1 levels peaked at 1 hour and remained at high levels for up to 24 hours. In contrast, IFN-γ treatment of TRIM14-deficient H1650 cells failed to induce sustained phospho-STAT1 levels, which decreased rapidly by 3 hours (Fig. 4e). Similar kinetics of STAT1 activation were observed in H358 cells when treated with IFN-γ. These results suggest that TRIM14 is required for STAT1 activation following IFN-γ stimulation. TRIM14 downregulation also significantly decreased transcription of well-characterized IFN-γ-inducible genes and STAT1 downstream targets in H1650 cells upon IFN-γ treatment (Fig. 4f). In control cells, quantitative RT-PCR using RNA extracted at 4 and 24 hours after IFN-γ treatment showed significantly increased levels of IFIT3, CDKN1A, OAS1 and ISG56 transcripts as compared to vehicle-treated cells. However, this enhancement was attenuated in the TRIM14-deficient cells indicating that TRIM14 is critical for STAT1-dependent gene expression.

Furthermore, recent studies have reported impaired type I IFN production in TRIM14−/− mice upon herpes simplex (HSV) infection17. Quantitative RT-PCR using RNA extracted from H1650 xenografted tumors showed significantly reduced IFN-β1 levels in TRIM14-deficient tumors compared to controls (Fig. 4g; p < 0.0001). Collectively, these results suggest that TRIM14 is a critical regulator in innate immune response and a mediator of IFN-γ-induced gene expression via STAT1 signaling.

Regulation of TRIM14 stability by proteasome degradation. To identify TRIM14 interacting proteins, we employed immunoprecipitation (IP) coupled with LC-MS/MS. HEK293T cells were transiently transfected with the full length TRIM14 ORF tagged at the C-terminus with 3xFLAG. FLAG-tagged TRIM14 complexes were isolated from total protein lysate by immunoprecipitation 48 hours after transfection and eluted transfected with the full length TRIM14 ORF tagged at the C-terminus with 3xFLAG. FLAG-tagged TRIM14 proteins, we employed immunoprecipitation (IP) coupled with LC-MS/MS. HEK293T cells were transiently transfected with the full length TRIM14 ORF tagged at the C-terminus with 3xFLAG. FLAG-tagged TRIM14 complexes were isolated from total protein lysate by immunoprecipitation 48 hours after transfection and eluted

Discussion
Here we report the first demonstration of tumor suppressive activity and immune regulation of TRIM14 in lung cancer cells. A pooled shRNA screen targeting genes of a 15-gene signature predictive of prognosis in NSCLC patients17 identified TRIM14 as impacting NSCLC cell proliferation/survival. The tumor suppressive function of TRIM14 was subsequently confirmed in several NSCLC cell line models both in vitro and in vivo.
Figure 4. TRIM14 sensitizes NSCLC cells to anoxic-induced cell death and Type II interferon response. (a) Cell cycle progression of isogenic cell lines was assessed by flow cytometry after propidium iodide (PI) staining to determine the percent distribution of G1, S or G2/M-phase cell populations. (b) MTS assay was used to measure cell viability of H1650 cells treated with serial dilutions of cisplatin for 48 hours. (c) H1650 and H358 cells cultured for 48 hours with a protein kinase inhibitor, Staurosporine (0.5 μM), or under anoxic conditions were fixed and stained for Annexin-V and PI. Flow cytometry was subsequently used to quantitate the percentage of Annexin-V positive cells after treatment. (d) Representative flow cytometry analysis of H1650 cells cultured with or without anoxic conditions. (e) H1650 and H358 cells were treated with or without 10 U IFN-γ for indicated times. Phosphorylation of STAT1 at tyrosine 701, total STAT1 and TRIM14 expression were analyzed by immunoblotting. (f) Quantitative RT-PCR using RNA extracted at 4 and 24 hours after IFN-γ treatment showed increased transcript levels of ISG56, P21, IFIT1, and OAS1 as compared to untreated cells, but this effect was significantly suppressed in TRIM14-deficient cells. (g) Quantitative RT-PCR was used to show that mRNA levels for TRIM14 and IFNB1 were significantly reduced in H1650 xenograft tumors compared to controls (n = 8 tumors with two technical replicates each). Results shown represent more than three biological replicates. (Two-tailed student's t-test; ****p < 0.0001).
| Identified Proteins (70) | Gene Symbol | Empty vector Exp. | TRIM14 Exp. |
|-------------------------|-------------|------------------|-------------|
|                         |             | 1 2 3            | 1 2 3       |
| 1 Tripartite motif-containing protein 14 | TRIM14     | 0 0 0            | 126 72 121  |
| 2 DNA-dependent protein kinase catalytic subunit | PRKDC    | 0 0 0            | 8 3 75     |
| 3 Isoform 2 of E3 ubiquitin-protein ligase HUWE1 | HUWE1   | 0 0 0            | 34 13 30   |
| 4 Isoform 5 of Protein transport protein | SEC16A | 0 0 0            | 9 23 21    |
| 5 CAD protein | CAD        | 0 0 0            | 13 4 29    |
| 6 E3 ubiquitin-protein ligase UBR5 | UBR5     | 0 0 0            | 13 2 19    |
| 7 Isoform 2 of Melanoma-associated antigen D1 | MAGED1 | 0 0 0            | 13 15 13   |
| 8 DnaJ homolog subfamily A member 2 | DNAJ2    | 0 0 0            | 5 4 12     |
| 9 Melanoma-associated antigen D2 | MAGED2   | 0 0 0            | 3 13 6     |
| 10 Translational activator GCN1 | GCN1L1    | 0 0 0            | 11 2 18    |
| 11 Sequestosome-1 p62 | SQSTM1   | 0 0 0            | 11 6 9     |
| 12 Bifunctional glutamate/proline--tRNA ligase | EPRS | 0 0 0            | 4 2 13     |
| 13 Serine/threonine-protein phosphatase 6 regulatory subunit 1 | PPP6R1 | 0 0 0            | 8 3 4      |
| 14 Isoform long of proteasome subunit alpha type-1 | PSMA1 | 0 0 0            | 9 4 5      |
| 15 Isoform 2 of HCLS1-associated protein X-1 | HAX1    | 0 0 0            | 4 5 6      |
| 16 Isoform 2 of Protein CIP2A | KIAA1524 | 0 0 0            | 4 2 4      |
| 17 E3 ubiquitin-protein ligase CHIP | STUB1    | 0 0 0            | 7 3 8      |
| 18 RuvB-like 2 | RUVBL2   | 0 0 0            | 6 5 8      |
| 19 26S proteasome non-ATPase regulatory subunit 4 | PSMD4 | 0 0 0            | 4 2 2      |
| 20 E3 ubiquitin-protein ligase Praja-1 | PJAI    | 0 0 0            | 4 6 2      |
| 21 Structural maintenance of chromosomes protein | SMC4 | 0 0 0            | 2 2 4      |
| 22 Isoform 2 of A-kinase anchor protein 12 | AKAP12  | 0 0 0            | 3 3 2      |
| 23 Programmed cell death protein 5 | PDCD5    | 0 0 0            | 2 4 2      |
| 24 Nucleosome assembly protein 1-like 4 (Fragment) | NAPI14  | 0 0 0            | 4 3 2      |
| 25 Proteasomal ubiquitin receptor ADRM1 | ADRM1   | 0 0 0            | 4 0 2      |
| 26 A-kinase anchor protein 8-like | AKAP8L   | 0 0 0            | 19 8 0     |
| 27 Apoptosis-inducing factor 1, mitochondrial | AIFM1   | 0 0 0            | 0 2 0      |
| 28 DnaJ homolog subfamily C member 7 | DNAJC7  | 0 0 0            | 12 6 0     |
| 29 Tubulin beta-8 chain | TUBB8    | 0 0 0            | 6 0 3      |
| 30 Immunoglobulin-binding protein 1 | IGBP1   | 0 0 0            | 5 0 3      |
| 31 Cancer/testis antigen family 45 member A5 | CT45A5  | 0 0 0            | 7 7 0      |
| 32 Tubulin beta-2A chain | TUBB2A   | 0 0 0            | 4 0 6      |
| 33 Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 | GBF1 | 0 0 0            | 0 2 5      |
| 34 DnaJ homolog subfamily B member 1 | DNAJB1   | 0 0 0            | 4 0 4      |
| 35 HEAT repeat-containing protein 6 | HEATR6   | 0 0 0            | 3 0 3      |
| 36 Structural maintenance of chromosomes protein 2 | SMC2 | 0 0 0            | 2 0 4      |
| 37 Serine/threonine-protein phosphatase 6 regulatory subunit 3 | PPP6R3 | 0 0 0            | 3 0 4      |
| 38 Proteasome subunit alpha type-7 | PSMA7    | 0 0 0            | 4 0 2      |
| 39 Prefoldin subunit 2 | PFDN2    | 0 0 0            | 0 5 2      |
| 40 La Ribonucleoprotein Domain Family Member 4B | LARP4B  | 0 0 0            | 2 7 0      |
| 41 Proteasome 26S Subunit, ATPase 6 | PSMC6    | 0 0 0            | 5 0 3      |
| 42 Tubulin beta-4A chain | TUBB4A   | 0 0 0            | 4 0 3      |
| 43 Isoform 1 of Fanconi anemia group 1 protein | FANC1   | 0 0 0            | 2 0 3      |
| 44 Pyridoxal-dependent decarboxylase domain-containing protein 1 | PDXD1C  | 0 0 0            | 0 2 6      |
| 45 Pre-mRNA-processing-splicing factor 8 | PRPF8    | 0 0 0            | 2 0 4      |
| 46 Isoform 2 of SAM domain and HD domain-containing protein 1 | SAMHD1  | 0 0 0            | 2 0 6      |
| 47 Pumilio homolog 1 | PUM1     | 0 0 0            | 0 3 3      |
| 48 S-phase kinase-associated protein 1 | SKP1     | 0 0 0            | 2 0 2      |
| 49 Isoform 2 of Cdc42 effector protein 1 | CDC42EP1 | 0 0 0            | 0 3 2      |
| 50 Tubulin beta-6 chain | TUBB6    | 0 0 0            | 3 0 3      |
| 51 Interleukin-1 receptor-associated kinase 1 | IRAK1   | 0 0 0            | 0 3 7      |
| 52 Methionyl-tRNA synthetase | MARS    | 0 0 0            | 2 0 5      |
| 53 Rho guanine nucleotide exchange factor 2 | ARHGEF2 | 0 0 0            | 2 4 0      |
| 54 BAG family molecular chaperone regulator 2 | BAG2    | 0 0 0            | 4 0 3      |
| 55 Isoform 2 of Caseinolytic peptidase B protein homolog | CLPB    | 0 0 0            | 4 0 2      |

Continued
Challenge and BR.10 expression datasets using Cox-regression analysis. Both univariate and multivariate sur-
expression in the Director's TRIM14 clinical outcome. Here, we confirmed the individual prognostic value of

derived from PML signaling cascades. How TRIM14 engages AIF in NSCLC remains unclear, but our results raise the possi-

ized tongue squamous cell carcinoma aggressiveness, an opposing phenotype to our observations in lung can-

TRIM27 α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–α–alpha...

Table 2. Top 70 proteins that co-immunoprecipitated with TRIM14 in HEK293T cells. Spectral counts for each of the three biological replicates are shown. Proteins in italic are involved in proteasome degradation.

| Identified Proteins (70) | Gene Symbol | Empty vector Exp. | TRIM14 Exp. |
|-------------------------|-------------|-------------------|-------------|
| 56 Acidic leucine-rich nuclear phosphoprotein 32 family member A | ANF32A | 0 0 0 2 2 0 |
| 57 Retinol dehydrogenase 1 | RCN1 | 0 0 0 2 2 0 |
| 58 Cysteine and glycine-rich protein 2 | CSRP2 | 0 0 0 2 4 0 |
| 59 Heat shock 70 kDa protein 4L | HSPA4L | 0 0 0 0 2 2 |
| 60 Protein SEC13 homolog | SEC13 | 0 0 0 2 0 2 |
| 61 RNA polymerase II-associated protein 1 | RPA1 | 0 0 0 2 0 4 |
| 62 26S proteasome non-ATPase regulatory subunit 6 f | PSMD6 | 0 0 0 2 0 2 |
| 63 Mitotic-spindle organizing protein 2A | MT2A | 0 0 0 0 2 2 |
| 64 Proteasome subunit alpha type-2 | PSMA2 | 0 0 0 2 0 2 |
| 65 Isoform 2 of RING finger protein 126 | RNF126 | 0 0 0 2 0 2 |
| 66 Tubulin alpha-1C chain | TUBA1C | 0 0 0 2 0 2 |
| 67 DNA damage-binding protein 1 | DDB1 | 0 0 0 2 0 2 |
| 68 DNA polymerase delta subunit 3 | POLD3 | 0 0 0 0 2 2 |
| 69 Proteasome activator complex subunit 3 | PSME3 | 0 0 0 3 0 2 |
| 70 Proteasome subunit alpha type-4 | PSMA4 | 0 0 0 3 0 2 |
| 71 Mitotic spindle-associated MMXD complex subunit MIP18 | FAM96B | 0 0 0 2 0 2 |

Supporting our animal studies is the in silico finding that low TRIM14 expression is correlated with worst clinical outcome. Here, we confirmed the individual prognostic value of TRIM14 expression in the Director's Challenge and BR.10 expression datasets using Cox-regression analysis. Both univariate and multivariate sur-

sclerotic keratinocytes (1%) in either lung adenocarcinoma or squamous carcinoma, suggesting that TRIM14 loss of function in NSCLC may be attributed to epigenetic regulation (http://www.cbioportal.org/). Across human cancer types, TRIM14 aberrations vary from amplifications in one cancer type and deletions in another, alluding to the possibility of tissue- and cell-type specific roles of TRIM14. Su et al.9 most recently reported that TRIM14 overexpression promoted tongue squamous cell carcinoma aggressiveness, an opposing phenotype to our observations in lung cancer cells. Interestingly, multivariate analysis also showed that TRIM14 expression did not correlate with survival in the University of Michigan study, which included only lung squamous carcinoma patients. Given that lung squamous carcinoma and adenocarcinomas are often considered two distinct diseases due to different mutation spectrums, we postulate that TRIM14 may behave differently in the two histological subtypes. Despite these phenotypical discrepancies between the current study and Su et al.9, both emphasize a pertinent role of aberrant TRIM14 expression in promoting carcinogenesis.

The TRIM family of proteins mediates a variety of biological processes. Alterations in TRIMs are associated with diverse pathological conditions, including developmental disorders, autoimmune disease, viral infections and cancer. A number of TRIMs, such as TRIM13, TRIM8, TRIM19 and TRIM26, function as tumor suppressor proteins by regulating transcriptional activity and apoptosis in a variety of cancer types. For instance, TRIM19, also known as Promyelocytic leukemia protein (PML), has a tumor suppressor function, and cells derived from PML−/− mice are defective in inducing apoptosis by Fas, TNFα, or interferons. TRIM27 also positively regulates TNF-α-induced apoptosis, and TRIM27−/− mice are resistant to TNF-α cytotoxicity. TRIM16, which along with TRIM14 lacks a RING finger domain, has been shown to reduce neuroblastoma and breast cancer cell growth and migration by activating caspase-2 to induce apoptosis. TRIM16−/− mice are resistant to TNF-α-induced apoptosis. In this study, xenografted tumors from TRIM14-deficient cells gave rise to faster tumor growth with markedly reduced apoptotic cells compared to its isogenic controls at necropsy. Because apoptotic pathways other than caspase activation exist, we further confirmed by Western blot analysis that silencing TRIM14 significantly reduced expression of AIF in vivo. Moreover, using Annexin-V staining by flow cytometry, we observed that TRIM14 downregulation significantly attenuated anoxia-induced apoptosis in both H1650 and H358 cells. Given that solid tumors often experience hypoxic conditions, we postulate that cells expressing TRIM14 confer sensitivity to apoptotic stimuli as reported for other TRIM protein members, resulting in retarded tumor growth compared to tumors lacking TRIM14. We also observed that TRIM14 co-immunoprecipitate eluates were enriched for apoptotic-related proteins (Table 2). In fact, AIF was among the proteins detected by mass spectrometry experiments and validated to bind with TRIM14 by independent co-immunoprecipitation assays (Fig. 5a,b). Indeed, previous studies showed that TRIM14 is localized to the outer mitochondria membrane and AIF is released from the mitochondria to induce apoptosis signaling cascades. How TRIM14 engages AIF in NSCLC remains unclear, but our results raise the possibility that caspase-independent cell death pathways may partly mediate TRIM14 tumor suppressive function. Collectively, our findings support the notion that TRIM14 may be acting via apoptotic/cell death pathways to exert its tumor suppressive phenotype. Further studies on the exact mechanism by which TRIM14 mediates these pathways will be of great interest.
A systematic analysis of all 75 known human TRIMs revealed that nearly half of these proteins could enhance the innate immune response. Emerging evidence suggests that the outgrowth of cancer cells into clinically detectable tumors requires immunoediting to reduce cellular immunogenicity and to escape the immune recognition that otherwise would lead to cancer cell elimination or growth inhibition. Among the many immunoregulatory cytokines, the type II IFNs are potent regulators of most effector cells involved in anti-tumor immune responses. Here we demonstrated for the first time that TRIM14 positively regulates type II IFN signaling in lung cancer cells. Silencing TRIM14 attenuated STAT1 pathway activation induced by IFN-γ in a time-dependent manner. Moreover, we showed that TRIM14 downregulation significantly decreased the mRNA

Figure 5. TRIM14 protein stability is regulated by ubiquitin-proteasome system. (a) Whole-cell extracts from HEK293T cells transfected with either empty FLAG vector or vector ectopically expressing FLAG-TRIM14 were immunoprecipitated with anti-FLAG antibody, and immune complexes were blotted with indicated antibodies. The ectopically expressed TRIM14 bound with endogenous AIF and HAX1 in HEK293T cells. (b) Conversely, endogenous TRIM14 was immunoprecipitated using anti-AIF antibody in HEK293T cells. (c) Ectopically expressed FLAG-TRIM14 immunoprecipitated with endogenous p62 in HEK293T cells. (d) H1395 cells. (e) Mass spectrometry analysis of FLAG-TRIM14 complexes independently showed that TRIM14 interacted with a number of E3 ubiquitin ligases and proteasome activators in HEK293T cells. (f) HEK293T cells were transiently transfected with the indicated vectors and were treated with or without 10 μM MG132 for 4 hours demonstrating that ubiquitylation of FLAG-TRIM14 is elevated in the presence of MG132. (g) HEK293T cells were treated with either DMSO or 10 μM MG132 for 4 hours before the addition of 100 μg/ml of cycloheximide (CHX). Immunoblot analysis was performed on HEK293T cell lysates at the indicated times post-cycloheximide treatment to determine TRIM14 protein stability. (h) Immunoblot analysis was done on H520 cells treated with either vehicle (DMSO) or Bortezomib (10 nM) at indicated time points. Abbreviations: IgG = immunoglobulin G, IP = Immunoprecipitation and IB = Immunoblotting.
levels of well-known STAT1 downstream targets, such as CDKN1, ISG56 and OAS1 upon IFN-γ induction. Earlier studies on TRIM19 showed that IFN-γ-mediated STAT1 DNA-binding activity and apoptosis were reduced in PML−/− mouse embryonic fibroblasts (MEFs) compared with wild-type MEFs. Until recently, Chen et al. demonstrated that TRIM14−/− mice were highly susceptible to IFN-γ infection due to impaired type I IFN production. Mechanistically, the authors revealed that TRIM14 stabilizes cyclic GMP-AMP synthase (cGAS), a DNA sensor that triggers IFN signaling, by inhibiting cGAS degradation via selective autophagy receptor p62. Here, we demonstrate for the first time that p62 (SQSTM1) immunoprecipitates with TRIM14 in both HEK293T and H1395 lung cancer cells (Fig. 5c,d). Such co-immunoprecipitation may be due to multi-component TRIM14-cGAS-p62 complex pull-down or an unexplored mechanism by which TRIM14 stabilizes cGAS by blocking p62. Moreover, we also show that IFN-γ mRNA levels are significantly reduced in TRIM14-deficient xenograft tumors compared to controls (Fig. 4g). Given that prior studies have demonstrated that STAT controls anti-tumorigenic effects in part by upregulation of caspases, p21 and the IFN-regulated factor 1 (IRF1) pathway, we postulate that lung cancer cells may suppress TRIM14 to promote tumorigenicity through immune escape5,6,36. It would be interesting to examine whether cells with TRIM14 expression in cancer cells are more susceptible to IFN anti-proliferative effects in immunocompetent animal models.

In conclusion, our findings provide the first in vitro and in vivo evidence that TRIM14 has a tumor suppressive role in lung cancer. Consistent with our initial genetic screen, TRIM14 expression in clinical samples correlated with poorer survival outcome. Overexpression of TRIM14 reduced cell viability, tumorigenicity, apoptosis as well as Type II interferon response. Our results provide new insights into the pathogenesis of NSCLC and highlight TRIM14 as a potential tumor suppressor and regulator of innate immune response in NSCLC cells.

References
1. Jemal, A. et al. Global cancer statistics. CA. Cancer J. Clin. 61, 69–90, doi: 10.3322/caac.20107 (2011).
2. Wao, H., Mhashkar, R., Kumar, A., Miladinovic, B. & Djulbegovic, B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Systematic reviews 2, 10, doi: 10.1186/2046-4053-2-10 (2013).
3. Reymond, A. et al. The tripartite motif family identifies cell compartments. Embo j 20, 2140–2151, doi: 10.1093/emboj/20.9.2140 (2001).
4. Tarantal, V. Z. et al. Differential gene expression in B-cell non-Hodgkin's lymphoma of SIV-infected monkey. AIDS Res. Hum. Retroviruses 16, 173–179, doi: 10.1089/088922200309511 (2000).
5. Tarantal, V. et al. Detection of abundantly transcribed genes and gene translation in human immunodeficiency virus-associated non-Hodgkin's lymphoma. Neoplasia 3, 132–142, doi: 10.1038/sj.neo/7900137 (2001).
6. Hirose, S., Nishizumi, H. & Sakano, H. Pub, a novel PU.1 binding protein, regulates the transcriptional activity of PU.1. Biochem. Biophys. Res. Commun. 311, 351–360 (2003).
7. Zhou, Z. et al. TRIM14 is a mitochondrial adaptor that facilitates retinoic acid-inducible gene-1-like receptor-mediated innate immune response. Proc. Natl. Acad. Sci. USA 111, E245–254, doi: 10.1073/pnas.1316941111 (2014).
8. Nenasheva, V. et al. Enhanced expression of trim14 gene suppressed Sindbis virus reproduction and modulated the transcription of a large number of genes of innate immunity. Immuno Res 62, 255–262, doi: 10.1007/s10206-015-8633-z (2015).
9. Su, X. et al. Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NF-kappaB signaling pathway. Oncotarget 7, 9939–9950, doi: 10.18632/oncotarget.6941 (2016).
10. Zhu, C. et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28, 4417–4424, doi: 10.1200/jco.2009.26.4325 (2010).
11. Winton, T. et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352, 2589–2597, doi: 10.1056/NEJMoa034323 (2005).
12. Sheddlen, K. et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14, 822–827, doi: 10.1038/nm.1790 (2008).
13. Raponi, M. et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66, 7466–7472, doi: 10.1158/0008-5472.can-06-1191 (2006).
14. Der, S. D. et al. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thorac Oncol 9, 56–64, doi: 10.1097/jto.0000000000000042 (2014).
15. Radulovich, N., Leung, L. & Tsao, M. S. Modified gateway system for double shRNA expression and Cre/lox based gene expression. Mol. Cell. 31, 354–360, doi: 10.1016/j.molcel.2016.08.025 (2016).
16. Keller, A., Nesvizhskii, A. I., Kolker, E. & Aebersold, R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74, 5383–5392 (2002).
17. Zhu, C. et al. Prognostic gene expression signature for squamous cell carcinoma of the lung. Clin Cancer Res 16, 5038–5047, doi: 10.1158/1078-0432.ccrr-10-0612 (2010).
18. Sho, T. et al. TRIM29 negatively regulates p53 via inhibition of Tip60. Biochem. Biophys. Acta 1813, 1245–1253, doi: 10.1016/j.bbamcr.2011.03.018 (2011).
19. Hatakeyama, S. TRIM proteins and cancer. Nature reviews. Cancer 11, 792–804, doi: 10.1038/nrc3139 (2011).
20. Tomar, D. et al. TRIM13 regulates caspase-8 ubiquitination, translocation to autophagosomes and activation during ER stress induced cell death. Biochem. Biophys. Acta 1833, 3134–3144, doi: 10.1016/j.bbamcr.2013.08.021 (2013).
21. Micale, L. et al. TRIM8 downregulation in glioma affects cell proliferation and it is associated with patients survival. BMC Cancer 15, 470, doi: 10.1186/s12885-014-1449-9 (2015).
22. Wang, Y. et al. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis. Biochem. Biophys. Res. Commun. 463, 458–465, doi: 10.1016/j.bbrc.2015.05.117 (2015).
23. Wang, Z. G. et al. PML is essential for multiple apoptotic pathways. Nat Genet 20, 266–272, doi: 10.1038/37073 (1998).
24. Zaman, M. M. et al. Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol 33, 4971–4984, doi: 10.1128/mcb.00465-13 (2013).
25. Marshall, G. M. et al. TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells. Oncogene 29, 6172–6183, doi: 10.1038/onc.2010.340 (2010).
26. Kim, P. Y. et al. TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells. Apoptosis: an international journal on programmed cell death 18, 639–651, doi: 10.1007/s10495-013-0813-y (2013).
27. Tomar, D. et al. TRIM4 as a novel mitochondrial interacting RING E3 ligase, sensitizes the cells to hydrogen peroxide (H2O2) induced cell death. Free Radic. Biol. Med. 89, 1036–1048, doi: 10.1016/j.freeradbiomed.2015.10.425 (2015).
30. Ryu, Y. S. et al. TRIM32 protein sensitizes cells to tumor necrosis factor (TNFalpha)-induced apoptosis via its RING domain-dependent E3 ligase activity against X-linked inhibitor of apoptosis (XIAP). J Biol Chem 286, 25729–25738, doi: 10.1074/jbc.M111.241893 (2011).
31. Susin, S. A. et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397, 441–446, doi: 10.1038/17135 (1999).
32. Versteeg, G. A. et al. The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors. Immunity 38, 384–398, doi: 10.1016/j.immuni.2012.11.013 (2013).
33. Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989–2003, doi: 10.1084/jem.20101158 (2011).
34. El Bougrini, J., Dianoux, L. & Chelbi-Alix, M. K. PML positively regulates interferon gamma signaling. Biochimie 93, 389–398, doi: 10.1016/j.biochi.2010.11.005 (2011).
35. Zhang, Y., Zhang, Y., Yun, H., Lai, R. & Su, M. Correlation of STAT1 with apoptosis and cell-cycle markers in esophageal squamous cell carcinoma. PLoS One 9, e113928, doi: 10.1371/journal.pone.0113928 (2014).
36. O’Donnell, L. A. et al. Interferon gamma induces protective non-canonical signaling pathways in primary neurons. J Neurochem 135, 309–322, doi: 10.1111/jnc.13250 (2015).

Acknowledgements
The authors thank Drs Scott Douglas, Kevin Brown, and Jeifei Tong for helpful discussions and analyses. We thank Drs Dan Cojocari and Brad Wouters for making the HypOxygen H85 workstation available to us. This study was supported by the Canadian Cancer Society Research Institute grant #020527, the Ontario Ministry of Health and Long Term Care, and the Princess Margaret Cancer Foundation. Dr. Wang was supported by the Terry Fox Foundation Training Program in Molecular Pathology of Cancer at CIHR. Dr. Tsao holds the M. Qasim Choksi Chair in Lung Cancer Translational Research. Dr. Shepherd holds the Scott Taylor Chair in Lung Cancer Research.

Author Contributions
Conception and design: J.H. and M.S.T. Development of methodology: J.H. and M.S.T. Experiments and interpretation of data: J.H., C.Z., T.W. and S.O. Writing, review and revision of the manuscript: J.H., C.Z., T.W., S.O., F.S. and M.S.T. Study supervision: F.S. and M.S.T.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Hai, J. et al. TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer. Sci. Rep. 7, 39692; doi: 10.1038/srep39692 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017